Creative Medical Technology Holdings, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
Creative Medical Technology Holdings, Inc. (CELZ) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of -$4.54 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-15.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2020-05-15
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2020-03-31 was -$4.54M.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2019-12-31 was $3.86M.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2019-09-30 was -$30.09K, a 104.24% decline year-over-year.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2019-06-30 was $416.46K, a 90.59% decline year-over-year.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2019 was $3.86M, a 56.67% decline from fiscal 2018.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2018 was $8.92M, a 1614.63% increase from fiscal 2017.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2017 was $520.08K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2020-03-31 | -$4.54M 10-Q · filed 2020-05-15 | -$686.25K derived: sum of 2 quarters · filed 2020-05-15 | -$716.34K derived: sum of 3 quarters · filed 2020-05-15 | -$299.87K derived: sum of 4 quarters · filed 2020-05-15 |
| 2019-12-31 | $3.86M derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-06 | $3.83M derived: sum of 2 quarters · filed 2020-04-06 | $4.24M derived: sum of 3 quarters · filed 2020-04-06 | $3.86M 10-K · filed 2020-04-06 |
| 2019-09-30 | -$30.09K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $386.38K derived: sum of 2 quarters · filed 2019-11-14 | $8.05K 10-Q · filed 2019-11-14 | -$2.71M derived: sum of 4 quarters · filed 2019-11-14 |
| 2019-06-30 | $416.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $38.14K 10-Q · filed 2019-08-13 | -$2.68M derived: sum of 3 quarters · filed 2019-08-13 | -$1.97M derived: sum of 4 quarters · filed 2019-08-13 |
| 2019-03-31 | -$378.32K 10-Q · filed 2019-05-20 | -$3.10M derived: sum of 2 quarters · filed 2019-05-20 | -$2.39M derived: sum of 3 quarters · filed 2019-05-20 | $2.03M derived: sum of 4 quarters · filed 2019-05-20 |
| 2018-12-31 | -$2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | -$2.01M derived: sum of 2 quarters · filed 2019-04-01 | $2.41M derived: sum of 3 quarters · filed 2019-04-01 | $8.92M 10-K · filed 2019-04-01 |
| 2018-09-30 | $710.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $5.14M derived: sum of 2 quarters · filed 2018-11-14 | $11.64M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $4.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $10.93M 10-Q · filed 2018-08-14 | ||
| 2018-03-31 | $6.51M 10-Q · filed 2018-08-03 | |||
| 2017-12-31 | $520.08K 10-K · filed 2018-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |